01359nas a2200421   4500000000100000000000100001008004100002653001100043653002800054653004400082653002600126653004000152653003000192653002200222653003100244653003800275653002400313653002600337653002800363653000900391653002200400653002500422653004200447653002300489100001500512700001300527700001300540700001200553700001500565700001200580700001500592700001500607245025000622250001500872300001200887490000700899020003100906       2023                            d10aHumans10a*Muscarinic Antagonists10a*Pulmonary Disease, Chronic Obstructive10aRetrospective Studies10aAdrenergic beta-2 Receptor Agonists10aNebulizers and Vaporizers10aDrug Combinations10aAdministration, Inhalation10aPatient Acceptance of Health Care10aPrimary health care10aBronchodilator Agents10aAdrenal Cortex Hormones10aCopd10aclinical outcomes10aprimary care setting10asingle-inhaler LAMA/LABA dual therapy10atreatment patterns1 aG. Requena1 aV. Banks1 aA. Czira1 aR. Wood1 aT. Tritton1 aR. Wild1 aC. Compton1 aA. Ismaila00aTreatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England  a2023/03/14  a231-2450 v18  a1176-9106 (Print)1176-9106